A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response

MDS Clinical Trial

Official title:

A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02197676
• Other study ID #: GFM-SGI-110
• Status: Completed
• Phase: Phase 2
• Start date: August 4, 2014
• Est. completion date: April 23, 2018

Study information

• Verified date: December 2018
• Source: Groupe Francophone des Myelodysplasies
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Treatment of patients with WHO defined IPSS int 2 and high risk MDS , AML with 20-30% marrow blasts and CMML type 2, after failure of azacitidine or decitabine exposure for at least 6 courses, or relapse after initial response.

Description:

All eligible patients will be treated with SGI-110 for 9 cycles of 28 days.

Patients who meet eligibility criteria will be administered subcutaneous SGI-110 at 60mg/m²/d one time daily for 5 days. Each cycle will last 28 days with SGI-110 starting on day 1 of each cycle. Patients will receive at least 9 cycles unless overt progression is documented. (Overt progression will be defined by the presence of more than 30% marrow blasts and doubling of marrow blast percentage from onset of SGI-110). Dose reduction to 45 and even 30 mg/m²/d will be made in case of toxicity.

Patients with Complete Remission (CR), Partial Remission (PR), marrow CR, Hematological Improvement (HI) or stable disease (SD) after 6 Cycles of therapy (IWG 2006 criteria) may receive 3 additional cycles. Response will be re-evaluated after 9 cycles. Patients with no response (NR) to treatment after 9 cycles will be withdrawn from the protocol. Patients with progression at any time will be withdrawn from the protocol after the last treatment Cycle.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: April 23, 2018
• Est. primary completion date: February 6, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Myelodysplastic syndrome including the following categories of the WHO classification:

refractory anemia with excess blasts (RAEB), non-proliferative chronic myelomonocytic leukemia (CMML) (leukocytes < 13 G/L but > 10% marrow blasts), AML with 20-30% marrow blasts (RAEB-T according to the FAB classification), at screening time.

• Prior treatment with azacitidine or decitabine for at least 6 courses without response(CR, PR, marrow CR or stable disease with HI according to IWG 2006 criteria) or relapsing after a response. Non responders will be eligible only in the absence of overt progression, ie AML progression (if patients had no AML at onset of azacitidine/decitabine) or doubling of marrow blast percentage between onset of azacitidine/decitabine and screening

• IPSS score >1 (IPSS: Int-2 or High).

• Age = 18 years.

• Normal liver function, defined by total bilirubin and transaminases less than 1.5 times the upper limit of normal.

• Normal renal function, defined by creatinine less than 1.5 times the upper limit of normal, creatinine clearance = 50 mL/min.

• Patient is known not to be refractory to platelet transfusions.

• Written informed consent.

• Patient must understand and voluntarily sign consent form.

• Patient must be able to adhere to the visit schedule as outlined in the study and follow protocol requirements.

• ECOG performance status between 0-2 at the time of screening.

• Women of chilbearing potential* must:

1. Understand the study drug is expected to have a teratogenic risk

2. Agree to have a medically supervised pregnancy test on the day of the study visit or in the 3 days prior to the study visit once the subject has been on effective contraception for at least 4 weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence. The test should ensure the subject is not pregnant when she starts treatment.

3. Agree to have a medically supervised pregnancy test every 4 weeks including 2 months after the end of study treatment, except in the case of confirmed tubal sterilization. These pregnancy tests should be performed on the day of the study visit or in the 3 days prior to the study visit. This requirement also applies to women of childbearing potential who practice complete and continued abstinence

4. Agree to use, and to be able to comply with, Two medically acceptable contraceptive measures without interruption, 4 weeks before starting study drug throughout the entire duration study drug therapy (including doses interruptions) and for 2 months after the end of the study drug therapy even if she has amenorrhoea. This applies unless the subject commits to absolute and continuous abstinence confirmed on a monthly basis, to avoid pregnancy for the duration of study.

5. Understand that even if she has amenorrhea, she must follow all the advice on effective contraception.

6. She understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy

• Men must: Agree to not conceive during the treatment and to use effective contraception during the treatment period (including periods of dose reduction or temporary suspension) and for a further 2 3 months after the end of treatment if their partner is of childbearing potential.

Exclusion Criteria:

• Severe infection or any other uncontrolled severe condition.

• Significant cardiac disease - NYHA Class III or IV or having suffered a myocardial infarction in the last 6 months.

• Less than 30 days since prior treatment with growth factors (EPO, G-CSF).

• Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea. The patient must have recovered from all acute toxicities from any previous therapy.

• Active cancer, or cancer during the year prior to trial entry other than basal cell carcinoma, or carcinoma in situ of the cervix or breast.

• Patient already enrolled in another therapeutic trial of an investigational drug.

• HIV infection or active hepatitis B or C.

• Women who are or could become pregnant or who are currently breastfeeding.

• Any medical or psychiatric contraindication that would prevent the patient from understanding and signing the informed consent form.

• Patient eligible for allotransplantation.

• Known allergy to SGI-110 or any of its excipients.

• No affiliation to an insurance system.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Leukemia, Myelomonocytic, Acute
• Leukemia, Myelomonocytic, Chronic
• Leukemia, Myelomonocytic, Juvenile
• MDS
• Myelodysplastic Syndromes
• Preleukemia

Intervention

Drug:
• SGI-110 administration
SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression. A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle.

Locations

Country	Name	City	State
France	CH Angers	Angers
France	CH Avignon	Avignon
France	Centre Hospitalier de La Cote Basque	Bayonne
France	Hôpital Avicenne	Bobigny
France	CHU Clémenceau	Caen
France	CHU Henri Mondor	Créteil
France	CHU de Grenoble	Grenoble
France	Centre Hospitalier du Mans	Le Mans
France	CHRU Limoges	Limoges
France	CH Lyon Sud	Lyon
France	Hôpital Paoli Calmettes	Marseille
France	Centre Hospitalier de Meaux	Meaux
France	Clinique Beausoleil (Montpellier)	Montpellier
France	Centre Catherine de Sienne (Nantes)	Nantes
France	CHU de nantes	Nantes
France	CHU de Nice - Hopital de l'Archet 1	Nice
France	CHR Orléans	Orléans
France	Hopital St Louis T4	Paris
France	Centre Hospitalier Joffre	Perpignan
France	CHU de Haut-Lévèque	Pessac
France	CHU de Poitiers	Poitiers
France	Centre Hospitalier de la région d'Annecy	Pringy
France	Centre Henri Becquerel	Rouen
France	Chu Purpan	Toulouse
France	Hopital Purpan Service d'Hématologie Clinique	Toulouse
France	CHU Bretonneau	Tours
France	CHU Brabois	Vandœuvre-lès-Nancy

Sponsors (2)

Lead Sponsor	Collaborator
Groupe Francophone des Myelodysplasies	Astex Pharmaceuticals

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate	Number of complete Remission (CR), CR with incomplete hematological recovery (CRi), Partial Remission (PR), Marrow CR and Hematological Improvement (HI) according to IWG 2006 criteria after 6 treatment cycles	6 month
Secondary	Duration of response	Measured from the date an objective response was achieved to the date of relapse or progression (cf. definition in appendix 5) or the date of last contact if no event occurred.	4 years
Secondary	Adverse event	Patients must have received at least one dose of treatment in order to be considered evaluable for toxicity.	After 1 month